MedTrace Logo

Japan Phase 2/3 Clinical Study With BLM-240 (Desflurane)

NCT00762372 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 216

Last updated 2019-03-08

Study results available
· View outcomes & findings →

Summary

The purposes of this study are to evaluate the efficacy and safety of desflurane (BLM-240) as an anesthetic agent and to demonstrate the non-inferiority of desflurane to sevoflurane in term of awakening/recovery from anesthesia.

Conditions

  • Anesthesia

Interventions

DRUG

desflurane

volatile liquid for inhalation

DRUG

desflurane/nitrous oxide

volatile liquid for inhalation with gas for inhalation

DRUG

sevoflurane/nitrous oxide

volatile liquid for inhalation and gas for inhalation

Sponsors & Collaborators

  • Baxter Healthcare Corporation

    lead INDUSTRY

Principal Investigators

  • Junzo Takeda, MD · School of Medicine, Keio University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00762372 on ClinicalTrials.gov